-
Posted by
Two Blokes Jun 23 -
Filed in
Stock
-
3 views
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences\u00ae Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy (“TriSalus” or the “Company”), today announced that it has commenced an exchange offer and consent solicitation involving its Series A Convertible Preferred Stock (the “Preferred Stock”) identified in the Prospectus/Offer to Exchange (as defined below). TriSal.
